- Home
- PRME vs RIGL Comparison
PRME vs RIGL Comparison
Compare PRME & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | RIGL |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 564.7M |
| IPO Year | 2022 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PRME | RIGL |
|---|---|---|
| Price | $3.43 | $29.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $7.56 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 1.6M | 313.7K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 1867.68 |
| EPS | N/A | ★ 19.48 |
| Revenue | $4,632,000.00 | ★ $294,282,000.00 |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $47.01 | $12.75 |
| P/E Ratio | ★ N/A | $1.48 |
| Revenue Growth | 55.28 | ★ 64.15 |
| 52 Week Low | $1.11 | $16.88 |
| 52 Week High | $6.94 | $52.24 |
Technical Indicators
Market Signals| Indicator | PRME | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 46.01 |
| Support Level | $3.17 | $28.08 |
| Resistance Level | $3.97 | $30.59 |
| Average True Range (ATR) | 0.20 | 1.13 |
| MACD | -0.03 | -0.22 |
| Stochastic Oscillator | 11.03 | 16.16 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.